Submitted:
05 March 2024
Posted:
06 March 2024
You are already at the latest version
Abstract
Keywords:
Introduction
Methods
Technical Description
Statistical Analysis
Results
Survival Analysis
Discussion
References
- Brunschwig, A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer 1948, 1, 177–183. [Google Scholar] [CrossRef] [PubMed]
- Ryan, O.K.; Doogan, K.L.; Ryan, J.; et al. Comparing minimally invasive surgical and open approaches to pelvic exenteration for locally advanced or recurrent pelvic malignancies - Systematic review and meta-analysis. European Journal of Surgical Oncology. [CrossRef] [PubMed]
- Pomel, C.; Rouzier, R.; Pocard, M.; et al. Laparoscopic total pelvic exenteration for cervical cancer relapse. Gynecologic Oncology 2003, 91, 616–618. [Google Scholar] [CrossRef] [PubMed]
- Dindo, D.; Demartines, N.; Clavien, P.-A. Classification of surgical complications. Ann. Surg. 2004, 240, 205–213. [Google Scholar] [CrossRef] [PubMed]
- Pontes García, A.; Durán Martínez, M.; Arjona Sánchez, Á.; et al. Laparoscopic Total Pelvic Exenteration in previous treated patient with endometrial carcinoma relapse. Colorectal Disease 2021. [Google Scholar] [CrossRef] [PubMed]
- Camilleri-Brennan, J.; Steele, R.J. The impact of recurrent rectal cancer on quality of life. Eur. J. Surg. Oncol. 2001, 27, 349. [Google Scholar] [CrossRef] [PubMed]
- Peeters, K.C.; Marijnen, C.A.; Nagtegaal, I.D.; et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 2007, 246, 693. [Google Scholar] [CrossRef] [PubMed]
- Brown, W.E.; Koh, C.E.; Badgery-Parker, T.; Solomon, M.J. Validation of MRI and Surgical Decision Making to Predict a Complete Resection in Pelvic Exenteration for Recurrent Rectal Cancer. Dis. Colon Rectum. 2017, 60, 144. [Google Scholar] [CrossRef] [PubMed]
- Koh, C.E.; Solomon, M.J.; Brown, K.G.; et al. The Evolution of Pelvic Exenteration Practice at a Single Center: Lessons Learned from over 500 Cases. Dis. Colon Rectum. 2017, 60, 627. [Google Scholar] [CrossRef] [PubMed]
- Kishan, A.U.; Voog, J.C.; Wiseman, J.; et al. Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. Br. J. Radiol. 2017, 90, 20170134. [Google Scholar] [CrossRef] [PubMed]
- Voogt, E.L.K.; van Zoggel, D.M.G.I.; Kusters, M.; et al. Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer. Ann. Surg. Oncol. 2020, 27, 3503. [Google Scholar] [CrossRef] [PubMed]
- Berek, J.S.; Howe, C.; Lagasse, L.D.; Hacker, N.F. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol. Oncol. 2005, 99, 153. [Google Scholar] [CrossRef] [PubMed]
- Höckel, M.; Dornhöfer, N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006, 7, 837. [Google Scholar] [CrossRef] [PubMed]
- Stanhope, C.R.; Symmonds, R.E. Palliative exenteration--what, when, and why? Am. J. Obstet. Gynecol. 1985, 152, 12. [Google Scholar] [CrossRef] [PubMed]
- Carvalho, F.; Qiu, S.; Panagi, V.; et al. Total Pelvic Exenteration surgery - Considerations for healthcare professionals. EJSO 2023, 49, 225–236. [Google Scholar] [CrossRef] [PubMed]
- PelvEx Collaborative. Perioperative management and anaesthetic considerations in pelvic exenterations using Delphi methodology: Results from the PelvEx Collaborative. BJS Open 2021, 5, 55. [Google Scholar]
- Prete, F.P.; Pezzolla, A.; Prete, F.; Testini, M.; Marzaioli, R.; Patriti, A.; et al. Robotic versus laparoscopic minimally invasive surgery for rectal cancer: A systematic review and meta-analysis of randomized controlled trials. Ann. Surg. 2018, 267, 1034–1046. [Google Scholar] [CrossRef] [PubMed]

| Total N (%) = 19 | LTPE N= 9 (47%) | OTPE N= 10 (53%) | p value | |
|---|---|---|---|---|
| Gender | Male 6 (31,6%) Female 13 (68,4&) |
Male 1 (11,1%) Female 8 (88,9%) |
Male 5 (50%) Female 5 (50%) |
0,06 |
Type of tumor:
|
4 (21,1%) 1 (5,3%) 11 (57,9%) 1 (5,3%) 1 (5,3%) 1 (5,3%) |
1 (11,1%) 0 7 (77,8%) 1 (11,1%) 0 0 |
3 (30%) 1 (10%) 4 (40%) 0 1 (10%) 1 (10%) |
0,32 |
| Intention: Curative/Palliative | 17 (89%) / 2 (11%) | 8 (88%) / 1 (22%) | 9 (90%) / 1 (10%) | 0,93 |
| Intraoperative therapy | HIPEC= 1 (11,1%) | RIO = 1 (10%) | 0,36 | |
| Surgery time (minutes) | 387 +/- 93,14 | 407 +/- 79,44 | 367 +/- 106 | 0.34 |
| Length of stay (days) | 16.16 +/- 26,22 | 10.11 +/- 5,58 | 21.6 +/- 35,75 | 0.35 |
| Resection | R0 15 (78,9%) R1 2 (10,5%) R2 2 (10,5%) |
R0 8 (88.9%) R1 0 R2 1 (11,1) |
R0 7 (70%) R1 2 (20%) R2 1 (105) |
0,36 |
| Major morbidity (Clavien Dindo ≥III) | 8 (42,1%) | 4 (44,4%) | 4 (40%) | 0,30 |
| Follow-up (months) | 50 ± 32 | 30.7 ± 15.5 | 66.3 ± 3 4.1 | 0.4 |
| Overall Survival (excluded patients with palliative intent) | 11 (40.7%) | 5 (41%) | 6 (37%) | 0.46 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).